Guardant Health SEC Filings

Form 144 notice for Guardant Health, Inc. (GH) reporting a proposed sale of 116 common shares through Charles Schwab & Co., Inc. on 08/19/2025 with an aggregate market value of $6,846.00. The shares were acquired on 08/15/2025 via a restricted stock lapse from Guardant Health and the payment/nature is listed as equity compensation. The filer or seller identified in prior transactions is Musa Tariq, who sold shares on 05/19/2025 (116 shares, $4,645.00), 06/18/2025 (3,213 shares, $158,947.00), and 07/17/2025 (116 shares, $5,591.00). The form includes the standard representation that the seller has no undisclosed material adverse information.

Form 144 filed for Guardant Health, Inc. (GH) shows a planned sale of 26 shares of common stock to be executed on 08/19/2025 through Charles Schwab & Co., with an aggregate market value of $1,534.52. The filing reports the 26 shares were acquired on 08/15/2025 in a restricted stock lapse from Guardant Health as equity compensation. The issuer's outstanding shares are listed as 124,705,857. The notice also discloses three sales by the same person in the past three months: 2,626 shares on 06/16/2025 for $130,512.00, 26 shares on 06/18/2025 for $1,286.00, and 26 shares on 07/17/2025 for $1,253.00. The filer affirms no undisclosed material nonpublic information.

Insider reported acquisition of shares from restricted stock units. Manuel Hidalgo Medina, a director of Guardant Health, acquired 232 shares on 08/17/2025 at a reported price of $0, increasing his direct common stock holdings to 3,016 shares. The filing also reports the conversion/vesting of 232 restricted stock units on the same date, leaving 8,121 restricted stock units (reported as derivative securities) beneficially owned in a direct capacity. The RSU award was granted on July 17, 2024 and vests over four years, with 25% vesting at the one-year anniversary and the remaining 75% vesting monthly over the next three years. The form was signed via attorney-in-fact on 08/18/2025.

Guardant Health director Tariq Musa reported the vesting and conversion of 250 restricted stock units into common shares on 08/15/2025 at no cash price, increasing his direct common stock holdings to 7,574 shares. The filing shows he continues to hold 4,747 restricted stock units after the transaction. The RSUs were part of a grant dated March 6, 2023 that vests over four years with 25% vesting on the one-year anniversary (March 15, 2023) and the remainder vesting monthly over the following three years. The Form 4 was signed by an attorney-in-fact on 08/18/2025.

Myrtle S. Potter, a director of Guardant Health, Inc. (GH), reported a grant vesting on 08/15/2025 that resulted in the acquisition of 69 shares of common stock at no cash price. After the reported transaction Potter beneficially owns 18,265 shares. The filing lists the underlying award as Restricted Stock Units that vested in part earlier: 25% vested on October 15, 2022, with the remaining 75% scheduled to vest in substantially equal monthly installments over the following three years. The Form 4 was signed by an attorney-in-fact on 08/18/2025.

Guardant Health (GH) Form 4: Director Steve E. Krognes reported the automatic conversion of 154 restricted stock units (RSUs) into an equal number of common shares on 07/31/2025 (transaction code “M”). No shares were sold. The RSUs stem from an August 9 2022 grant that vested 25 % on 06/30/2023; the remaining 75 % continue to vest in equal monthly installments through mid-2026.

Following the conversion, Krognes now holds 17,973 shares directly and retains 1,698 un-settled RSUs. The transaction was priced at $0, indicating a standard equity award settlement rather than an open-market purchase. Ownership structure remains direct, and no 10b5-1 plan was indicated.